Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model.

Primary tabs

field_vote: 
Average: 7 (1 vote)
Publication type: 
Therapeutic intervention: 
Therapeutic Substance(s): 
References: 

World J Gastroenterol. 2008 Dec 28;14(48):7386-91.

Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model.
Liu HY, Huang ZL, Yang GH, Lu WQ, Yu NR.
Department
of Abdominal Surgery, Affiliated Tumor Hospital of Guangzhou Medical
College, Guangzhou 510095, Guangdong Province, China.

AIM: To discuss the
expression of glactin-3 in liver metastasis of colon cancer and its
inhibition by modified citrus pectin (MCP) in mice. METHODS:
Seventy-five Balb/c mice were randomly divided into negative control
group (n = 15), positive control group (n = 15), low MCP concentration
group (n = 15), middle MCP concentration group (n = 15) and high MCP
concentration group (n = 15). CT26 colon cancer cells were injected
into the subcapsule of mouse spleen in positive control group, low,
middle and high MCP concentrations groups, except in negative control,
to set up a colon cancer liver metastasis model. The concentration of
MCP in drinking water was 0.0%, 0.0%, 1.0%, 2.5% and 5.0% (wt/vol),
respectively. Liver metastasis of colon cancer was observed after 3 wk.
Enzyme-linked immunosorbent assay (ELISA) was used to detect the
concentration of galectin-3 in serum. Expression of galectin-3 in liver
metastasis was detected by immunohistochemistry. RESULTS: Except for
the negative group, the percentage of liver metastasis in the other 4
groups was 100%, 80%, 73.3% and 60%, respectively. The number of liver
metastases in high MCP concentration group was significantly less than
that in positive control group (P = 0.008). Except for the negative
group, the median volume of implanted spleen tumor in the other 4
groups was 1.51 cm(3), 0.93 cm(3), 0.77 cm(3) and 0.70 cm(3),
respectively. The volume of implanted tumor in middle and high MCP
concentration groups was significantly smaller than that in positive
control group (P = 0.019; P = 0.003). The concentration of serum
galectin-3 in positive control and MCP treatment groups was
significantly higher than that in the negative control group. However,
there was no significant difference between them. Except for the
negative control group, the expression of galectin-3 in liver
metastases of the other 4 groups showed no significant difference.
CONCLUSION: Expression of galetin-3 increases significantly in liver
metastasis of colon cancer, which can be effectively inhibited by MCP.